Therapeutic Potential of Heat Shock Protein 90 Inhibitors in Colorectal Cancer

Abstract

Colorectal cancer (CRC) is one of the most common causes of cancer- related death globally. Despite recent advances in diagnosis and treatment, CRC remains one of the leading cause mortality, with 5 years survival rate of approximately 60%. Hence, there is an urgent need for new therapeutic approaches. A large number of Hsp90 client proteins have importance in the stability and function of crucial oncogenic proteins and play critical roles in the development of CRC. Hence, Hsp90 inhibitors may have therapeutic benefits in the treatment of CRC, and they are currently in clinical trials for various malignancies. In this chapter, we have reviewed the potential role of Hsp90 in the pathogenesis of CRC, and have summarized recent preclinical and clinical studies of Hsp90 inhibitors as a potential therapeutic in CRC.